Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data provide valuable insights for everyday practice. A long-term goal of systemic psoriasis therapy is to erase the inflammatory memory and thus achieve a sustainable cure. Several research projects have therefore focused on tissue-resident memory T-cells.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Important basics and studies on cancer and the psyche